Overview

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Status:
NOT_YET_RECRUITING
Trial end date:
2028-03-27
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the effects of KAI-9531 subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Phase:
PHASE3
Details
Lead Sponsor:
Kailera